IDENIX PHARMACEUTICALS INC
IDIX
IDIX was delisted on the 5th of August, 2014.
93 hedge funds and large institutions have $521M invested in IDENIX PHARMACEUTICALS INC in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 17 closing their positions.
257% more call options, than puts
Call options by funds: $6.83M | Put options by funds: $1.91M
46% more capital invested
Capital invested by funds: $357M → $521M (+$164M)
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 97 → 93 (-4)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$12.7M |
| 2 |
1WCM
12 West Capital Management
New York
|
+$7.81M |
| 3 |
BM
Bridger Management
New York
|
+$4.82M |
| 4 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
+$3.51M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$9.93M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.64M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.21M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.13M |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$2.11M |
IDIX Hedge Fund Activity: Q3 2013 in Review
93 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in IDENIX PHARMACEUTICALS INC (IDIX) for Q3 2013, worth a combined $521M — up 46% from $357M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of IDIX and 14 opened new positions — a net loss of 3 holders — while 27 trimmed existing stakes and 34 added.
The largest buyer was Baupost Group, adding an estimated $12.7M. The largest seller was Camber Capital Management, exiting entirely with an estimated $9.93M sold.
- 93 institutional investors held IDENIX PHARMACEUTICALS INC (IDIX) as of Q3 2013, down from 97 in Q2 2013.
- Funds reported $521M of IDENIX PHARMACEUTICALS INC stock for Q3 2013, up 46% quarter-over-quarter.
- 14 funds opened new IDENIX PHARMACEUTICALS INC positions in Q3 2013 and 17 closed out, a net change of -3 holders.
- The largest IDENIX PHARMACEUTICALS INC buyer in Q3 2013 was Baupost Group, an estimated $12.7M added.
- The largest IDENIX PHARMACEUTICALS INC seller in Q3 2013 was Camber Capital Management, an estimated $9.93M sold.
Based on aggregated 13F filings for Q3 2013.